// App-Quantinova.ai

: A phase II study of cabozantinib as first-line treatment in metastatic collecting ducts carcinoma: The BONSAI trial.

Researchers

Presenter

  • Giuseppe Procopio

Principal Investigators

  • Raffaele Ratta

  • Maurizio Colecchia

  • Marialuisa Sensi

  • Pierangela Sepe

  • Melanie Claps

  • Licia Rivoltini

  • Filippo G. De Braud

  • Filippo Pagani

  • Elena Verzoni

Medical Centers

  • Division of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

Outcome

  • N/A

Study Design

  • Single Arm

  • Prospective

Phase

  • NA

Study Id's

  • NCT03354884

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved